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Abstract
Background
Chronic parasitic infections are associated with active immunomodulation which may
include by-stander effects on unrelated antigens. It has been suggested that pre-natal expo-
sure to parasitic infections in the mother impacts immunological development in the fetus
and hence the offspring’s response to vaccines, and that control of parasitic infection among
pregnant women will therefore be beneficial.
Methodology/Principal findings
We used new data from the Entebbe Mother and Baby Study, a trial of anthelminthic treat-
ment during pregnancy conducted in Uganda, to further investigate this hypothesis. 2705
mothers were investigated for parasitic infections and then randomised to albendazole
(400mg) versus placebo and praziquantel (40mg/kg) during pregnancy in a factorial design.
All mothers received sulfadoxine/pyrimethamine for presumptive treatment of malaria. Off-
spring received Expanded Programme on Immunisation vaccines at birth, six, 10 and 14
weeks. New data on antibody levels to diphtheria toxin, three pertussis antigens, Haemophi-
lus influenzae type B (HiB) and Hepatitis B, measured at one year (April 2004 –May 2007)
from 1379 infants were analysed for this report. Additional observational analyses relating
maternal infections to infant vaccine responses were also conducted. Helminth infections
were highly prevalent amongst mothers (hookworm 43.1%, Mansonella 20.9%, Schisto-
soma mansoni 17.3%, Strongyloides 11.7%, Trichuris 8.1%) and 9.4% had malaria at enrol-
ment. In the trial analysis we found no overall effect of either anthelminthic intervention on
the measured infant vaccine responses. In observational analyses, no species was
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associated with suppressed responses. Strongyloidiasis was associated with enhanced
responses to pertussis toxin, HiB and Hep B vaccine antigens.
Conclusions/Significance
Our results do not support the hypothesis that routine anthelminthic treatment during preg-
nancy has a benefit for the infant’s vaccine response, or that maternal helminth infection has
a net suppressive effect on the offspring’s response to vaccines.
Trial Registration
ISRCTN.com ISRCTN32849447
Author summary
Parasitic infections, such as worms and malaria, have potent effects on the human
immune system. These effects include modification of immune responses in the fetus
and infant if a mother has a parasitic infection during pregnancy. These immunological
changes can influence the way a child responds to the same infection when exposed in
later life. It has been suggested that the immunological changes might also influence how
the child responds to the vaccines given in infancy, and that treating mothers for para-
sitic infections when they are pregnant might be helpful. In this study we compared
responses to vaccines between infants of mothers who had, or had not, been treated for
worms while they were pregnant. We found no overall differences. We also compared
vaccine responses between groups of mothers with and without parasitic infections. We
found no evidence that the parasitic infections were associated with reduced responses
in the children. This means that, although treating worms during pregnancy may have
some benefits, improvements in the children’s responses to vaccines are not likely to be
among them.
Introduction
There is substantial evidence that pre-natal exposures are important in shaping immunological
development [1]. This includes strong evidence that prenatal exposure and sensitisation to par-
asite antigens determines susceptibility to the same parasite in the offspring [1] and that
immunisation during pregnancy influences the infant response to the same vaccine [2]. There
is also evidence that prenatal exposures may influence the offspring’s response to unrelated
antigens [1]. It is important to better understand such effects since they are likely to be impor-
tant in broadly determining susceptibility to infectious diseases, either directly or through
responses to immunisation, as well as determining susceptibility to other immunologically
mediated conditions (such as allergy-related disease [3, 4]). Vaccines provide an example of a
standardised immunological challenge given at a standardised time and hence an opportunity
to evaluate the effects of pre-natal exposures on infant immune responses.
Recently, Malhotra and colleagues reported a study among children of mothers infected or
uninfected with malaria and helminths in a coastal region of Kenya which suggested that
infants of parasite-infected mothers had a reduced ability to develop antibody responses to
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Haemophilus influenzae type B (HiB) immunisation and diphtheria toxoid (DT), but showed
no effect on responses to hepatitis B (Hep B) immunisation or tetanus toxoid (TT) [5].
If there is a causal association between prenatal parasitic exposure and infant vaccine
responses, then treatment of maternal parasitic infections might be expected to remove par-
asite-associated effects. We conducted a randomised controlled trial (the Entebbe Mother
and Baby Study, ISRCTN32849447) to investigate whether anthelmintic treatment of preg-
nant mothers improved the vaccine response amongst their children [6]. We have previ-
ously reported the effects of treatment on cellular responses following BCG and tetanus
immunisation, and on tetanus and measles antibody concentrations: there were no overall
effects but, in planned subgroup analyses, albendazole treatment of mothers with hook-
worm was associated with reduced T-helper 2 cytokine responses to TT in their infants, and
(unexpectedly) albendazole treatment of mothers without hookworm resulted in increased
interferon-γ(IFN-γ) responses to mycobacterial antigen; otherwise no effects of maternal
treatment on responses to BCG, TT or measles were observed [7]. Here, we report on the
effects of maternal anthelminthic treatment on a further six serological responses (DT, per-
tussis [pertussis toxin (PT), filamentous haemagglutinin (FHA) and pertactin], Hep B and
HiB).
In addition to the trial results, we also present an observational analysis of associations
between multiple maternal infections and infant immunological responses, analogous to the
observational analyses reported by Malhotra and colleagues, using our existing dataset to
investigate whether similar associations are also present in our cohort of mothers and babies
from rural and urban areas of central Uganda.
Methods
Study design and participants
Healthy pregnant mothers in their second or third trimester were enrolled as part of the
Entebbe Mother and Baby Study (EMaBS; ISRCTN32849447) between 2003 and 2005,
described elsewhere [6, 7]. Briefly, this was a randomised, placebo-controlled, factorial study
of the effect of single-dose albendazole (400 mg) and praziquantel (40 mg/kg) given during
the second or third trimester of pregnancy on postnatal outcomes. Mothers were enrolled at
their first antenatal visit unless they attended in the first trimester, in which case enrolment
was postponed to minimise risk of teratogenicity. After enrolment they continued to receive
standard antenatal care, including intermittent presumptive treatment for malaria with sulfa-
doxine/pyrimethamine and tetanus immunisation, and intrapartum and neonatal single-
dose nevirapine for prevention of mother-to-child HIV transmission for the minority in
whom it was required. Infants received the routine EPI (Expanded Programme on Immuni-
sation) vaccines (BCG and polio at birth; DT, pertussis toxin, TT, Hep B and HiB at age six,
10 and 14 weeks, measles at nine months). All mothers gave informed written consent on
behalf on themselves and their children. We have previously reported on responses to vac-
cines against tuberculosis, TT and measles [7]. Here we assess six immunological responses
amongst children at age one year: DT, Hep B, pertussis, FHA, pertactin, Hep B, and HiB.
Only children who received all three doses of pentavalent vaccine are included in this
analysis.
Ethical consent was granted for the original trial and for subsequent analysis from UVRI
(GC/127/12/07/32), the Uganda National Council for Science and Technology (MV625), Lon-
don School of Hygiene & Tropical Medicine (790, A340), and the Oxford Tropical Research
Ethics Committee (39–12).
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Maternal and infant infection status
At screening during pregnancy, and at delivery, or as soon as possible after delivery (for those
whose children were born outside hospital), blood samples were obtained from each woman
to test for presence of malaria parasites by thick film and for microfilariae of Mansonella per-
stans using a modified Knott’s method [8]; a single stool sample was obtained for diagnosis of
intestinal parasites including hookworm (Necator americanus in this area [9]), Schistosoma
mansoni, Trichuris trichiura and Ascaris lumbricoides using the Kato Katz technique [10] and
for Strongyloides stercoralis by culture [11].
In case of multiple births just the first child was considered for inclusion in this analysis.
Mother-baby pairs were excluded if the infant did not receive the standard three doses of EPI
vaccines before samples were collected.
At one-year of age a blood sample was obtained from infants. Plasma and serum were sep-
arated and stored at -80˚C until processing. Plasma or serum were assessed for antibody con-
centrations against DT, pertussis antigens and HiB using a Luminex bead-based multiplex
immunoassay described in detail elsewhere[12, 13]. Antibody concentrations against Hep B
were measured using the ABBOTT Architect i2000 with their anti-HBs kit (Abbott Laborato-
ries, Chicago IL, USA) using the recommended protocol. We elected to measure the unsti-
mulated serological response to vaccination in order to maintain consistency with other
published reports of helminth-vaccine response associations. In the cases of DT and HiB
these measures are likely correlated with protection against disease. In the case of pertussis it
remains unclear which antigen is responsible for inducing protection and whether serological
levels are sufficient correlates, whereas for hepatitis B, there is evidence that measuring peak
response of antibody (approximately 6 weeks post final vaccination) is the optimal correlate
of protection although practically this is very difficult to achieve [14].
Mothers were categorised by parasite exposure in three ways, following the approach of
Malhotra 2015 for comparability [5]. First, mothers were grouped according to the total num-
ber of infections (helminths and malaria: 0; 1; 2;3). Second, mothers were grouped as no
infection; malaria only; malaria plus one helminth infection; malaria plus two or more hel-
minth infections. Third, mothers without malaria were grouped as follows: no helminth infec-
tions; one infection and no malaria, two infections and no malaria; three or more infections
and no malaria.
Statistical analysis
The vaccines examined here were not the primary outcomes for this trial, so sample size calcu-
lations were not based on these responses. In a post-hoc evaluation of power, based upon the
standard deviations we observed, we had 80% power to detect differences ranging from 1.18
(FHA) to 1.34 (HiB). A complete case analysis was done where possible, and imputation of
missing data was not performed. Vaccine responses from the included and excluded records
were compared with t-tests or Mann-Whitney tests, as appropriate.
As this was a factorial trial, comparisons were made between all those randomised to alben-
dazole versus those randomised to matching placebo, and between praziquantel versus pla-
cebo. Linear regression was used to assess associations between exposures (albendazole and
praziquantel) and outcomes (infant vaccine responses). Outcome variables were transformed
onto the log (base 10) scale to reduce skew; hence reported coefficients represent geometric
mean ratios (GMR). Regression was performed with a bias-corrected bootstrap using 100 rep-
licates. Covariates were selected a priori and included maternal baseline characteristics of age,
parity (1; 2–4;5), education level (none; primary; secondary; tertiary), and household socio-
economic group (on a six point scale, with six representing the highest group); infant
Prenatal exposure to parasitic infections and anthelminthic treatment on responses to immunisations
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covariates were sex, infant malaria and time (in days) since the third EPI vaccination. Pre-
planned sub-group analysis was carried out to examine the effect of albendazole on children of
mothers who had a hookworm infection, and separately for the effect of praziquantel on the
children of mothers with S. mansoni infection. This was performed using the same regression
technique as described above and allowing an interaction between randomised treatment and
infection. Interaction effects between the two randomised treatments were tested in a similar
way.
A similar approach was used to assess individual infections (including binary indicator vari-
ables for malaria, hookworm, S. mansoni, M. perstans, Ascaris, Trichuris and strongyloidiasis
in one linear regression model) and the exposure categories defined above. In each case we
also adjusted for randomised treatment. Exposure groups were treated as categorical variables
designed to allow for a comparison with the previously published results from mothers in
Kenya [5].
No adjustment was made for the numerous testing caused by assessing the effect of multiple
exposures on six outcomes. Stata version 14.1 was used for all analyses.
Results
A total of 2507 mothers were enrolled into the trial [7]. We had complete vaccine response
data (excluding hepatitis B) for 1379 (55%) mothers and first-born babies: 348 were rando-
mised to albendazole + praziquantel, 346 to albendazole + placebo, 336 to praziquantel + pla-
cebo, and 349 to placebos only. Due to limited serum and plasma from infants, samples were
unavailable for Hepatitis B assay for 374 of these infants (Fig 1). The demographic character-
istics of these 1379 mothers were similar to those who were missing from our analysis. The
biggest difference was in maternal malaria infection: this was 9.4% in those included in the
analysis and 12.9% in those excluded. Other characteristics were broadly similar: average age
was 23.9 years (included) and 23.4 years (excluded); education was “none” or “primary” in
Fig 1. Flow of patients through the trial.
doi:10.1371/journal.pntd.0005213.g001
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54.7% in the included group and 54.5% in the excluded group. Hookworm infection was
43.2% and 45.3%, and S. mansoni infection was 17.3% and 19.7% in the included and
excluded groups respectively. The sex of the babies was also similar between the included
(49.6% female) and excluded groups (47.3% female), as was the parity of the mothers (mean
2.8 in both groups).
Baseline characteristics were broadly balanced between the randomised arms (Table 1). The
most common maternal infection among the mothers with vaccine response data was hook-
worm (43.1%), followed by Mansonella (20.9%), S. mansoni (17.3%), Strongyloides (11.7%),
malaria (9.4%), Trichuris (8.1%) and Ascaris (2.1%). We had stool samples for 1235 (89.6%) of
one-year olds. The most common parasites detected were Ascaris (n = 16) and Trichuris
(n = 12). We found very low levels of hookworm (n = 4) and S. mansoni (n = 1).
We found no evidence of an effect of randomised treatment on any of the infant vaccine
responses (Table 2), nor any evidence for treatment interaction (p>0.1 for all outcomes, S1
Table). In pre-planned sub-group analysis, the only evidence of a differential treatment effect
was on DT response in children of mothers who received albendazole: in mothers with hook-
worm the adjusted geometric mean ratio (aGMR) for albendazole was 0.89 (95 CI% 0.74–1.08)
and in mothers without hookworm it was 1.24 (95% CI 1.04–1.47). The p-value for interaction
was p = 0.01 (Table 3).
For the observational analysis, a total of 1286 mothers-baby pairs had known status for all
seven infections of interest and five of the six vaccines (Hepatitis B, n = 940). We found no evi-
dence of different vaccine response results in the excluded records. Similar to the trial analysis,
the most common maternal infection in this group was hookworm (43.1%), followed by Man-
sonella (21.2%), S. mansoni (16.7%), Strongyloidiasis (11.6%), malaria (9.2%), Trichuris (8.5%)
and Ascaris (1.9%).
We found no evidence that maternal infections were associated with infant vaccine
response except for maternal strongyloidiasis. The aGMR of HiB response for children of
mothers with strongyloidiasis was 1.51 times greater (95% CI 1.11–2.01) than children of
mothers who were uninfected. For Hep B the increase was by a factor of 1.47 (95% CI 1.11–
1.94) and in pertussis response the aGMR was 1.41 (95% CI 1.06–1.88). We found no evidence
of an association between any of the maternal exposure groups (number of infections, number
of infections alongside malaria, number of infections among mothers without malaria) and
any infant vaccine response at one year. Full results are in Table 4.
Discussion
We found no evidence of enhanced vaccine responses among infants of infected mothers who
were treated for helminths during pregnancy, nor evidence of a suppressive effect of prenatal
exposure to maternal parasitic infections on infant vaccine responses, in this cohort of mothers
and infants in Uganda. Such possible effects as were observed were indicative of enhanced
responses for a number of vaccines in the infants of mothers identified as having strongyloidia-
sis, and of reduced DT responses in the infants of mothers with detectable hookworm infection
who were treated with albendazole.
The primary strength of our study is the randomised, controlled intervention during preg-
nancy. Hookworm infection was treated effectively by albendazole (declining from over 40%
prevalence before treatment to 5% after delivery among albendazole treated women) and
schistosomiasis was treated effectively by praziquantel (declining from about 18% to 5%) while
Mansonella and Strongyloides were unaffected by the treatment [15]. From a simplistic per-
spective, the lack of effect of maternal treatment on vaccine responses among infants of
women infected with hookworm and S. mansoni implies either that prenatal exposure to these
Prenatal exposure to parasitic infections and anthelminthic treatment on responses to immunisations
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Table 1. Baseline characteristics of mothers whose children were enrolled into the study and provided samples at nine years of age.
Characteristic Albendazole + praziquantel
(n = 348)
Praziquantel only
(n = 336)
Albendazole only
(n = 346)
Placebo
(n = 349)
Mother’s age group
14–19 68 (20%) 82 (24%) 88 (25%) 72 (21%)
20–24 123 (35%) 129 (38%) 125 (36%) 144 (41%)
25–29 98 (28%) 78 (23%) 81 (23%) 74 (21%)
30–34 41 (12%) 32 (10%) 28 (8%) 44 (13%)
35+ 18 (5%) 15 (4%) 24 (7%) 15 (4%)
Mother’s education (2 missing
values)
None 11 (3%) 10 (3%) 10 (3%) 16 (5%)
Primary 181 (52%) 171 (51%) 182 (53%) 172 (49%)
Senior 124 (36%) 117 (35%) 134 (39%) 124 (36%)
Tertiary 32 (9%) 37 (11%) 20 (6%) 36 (10%)
Mother’s tribe (2 missing values)
Baganda 181 (52%) 173 (51%) 176 (51%) 167 (48%)
Banyankole 41 (12%) 20 (6%) 34 (10%) 40 (11%)
Batoro 11 (3%) 19 (6%) 11 (3%) 21 (6%)
Basoga 15 (4%) 8 (2%) 9 (3%) 10 (3%)
Luo 15 (4%) 25 (7%) 21 (6%) 18 (5%)
Banyarwanda 21 (6%) 15 (4%) 20 (6%) 19 (5%)
Others 64 (18%) 76 (23%) 75 (22%) 74 (21%)
Mother’s SES group (22 missing
values)
1 Lowest 16 (5%) 19 (6%) 14 (4%) 19 (6%)
2 26 (8%) 25 (8%) 34 (10%) 30 (9%)
3 105 (31%) 105 (32%) 94 (28%) 116 (34%)
4 101 (29%) 92 (28%) 90 (26%) 102 (30%)
5 73 (21%) 68 (21%) 87 (26%) 61 (18%)
6 Highest 22 (6%) 21 (6%) 21 (6%) 16 (5%)
Mother’s parity (22 missing values)
1 87 (25%) 90 (27%) 91 (26%) 86 (25%)
2–4 193 (55%) 191 (57%) 199 (58%) 209 (60%)
5+ 68 (20%) 55 (16%) 56 (16%) 54 (15%)
Hookworm (22 missing values)
No 189 (54%) 185 (55%) 214 (62%) 196 (56%)
Yes 159 (46%) 151 (45%) 132 (38%) 153 (44%)
S. mansoni (22 missing values)
No 292 (84%) 281 (84%) 284 (82%) 284 (81%)
Yes 56 (16%) 55 (16%) 62 (18%) 65 (19%)
Malaria (22 missing values)
No 321 (92%) 305 (91%) 311 (90%) 313 (90%)
Yes 27 (8%) 31 (9%) 35 (10%) 36 (10%)
Filariasis (22 missing values)
No 274 (79%) 266 (79%) 279 (81%) 272 (78%)
Yes 74 (21%) 70 (21%) 67 (19%) 77 (22%)
Ascaris (22 missing values)
No 343 (99%) 328 (98%) 339 (98%) 340 (97%)
Yes 5 (1%) 8 (2%) 7 (2%) 9 (3%)
(Continued )
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helminth species has no important effect on the infant response to unrelated vaccines (and
hence perhaps to unrelated infections), or that the impact of prenatal exposure is established
prior to the second trimester and cannot be reversed thereafter. Of note, Malhotra and col-
leagues treated all mothers with albendazole (for nematodes) during pregnancy; we, and Mal-
hotra and colleagues, treated all mothers with sulfadoxine / pyrimethamine (for malaria); the
Table 1. (Continued)
Characteristic Albendazole + praziquantel
(n = 348)
Praziquantel only
(n = 336)
Albendazole only
(n = 346)
Placebo
(n = 349)
Trichuris (22 missing values)
No 320 (92%) 306 (91%) 320 (92%) 321 (92%)
Yes 28 (8%) 30 (9%) 26 (8%) 28 (8%)
Strongyloidiasis (22 missing values)
No 301 (86%) 297 (88%) 308 (89%) 311 (89%)
Yes 47 (14%) 39 (12%) 38 (11%) 38 (11%)
doi:10.1371/journal.pntd.0005213.t001
Table 2. The effect of randomised maternal treatment on antibody concentrations among infants at one year of age.
Antibody concentrations Geometric mean Geometric mean ratio (95% CI)* Geometric mean Geometric mean ratio (95% CI)*
Albendazole Placebo Praziquantel Placebo
HiB (g/ml) 0.89 0.78 1.14 (0.93–1.39) 0.8 0.87 0.92 (0.75–1.13)
Diphtheria (Dtox IU/ml) 0.03 0.03 1.07 (0.94–1.22) 0.03 0.03 0.93 (0.82–1.05)
Hepatitis B (mIU/ml) 99.94 97.27 1.03 (0.86–1.23) 90.41 106.88 0.85 (0.71–1.01)
Pertussis toxin (Ptx EU/ml) 10.78 9.02 1.20 (0.99–1.44) 9.92 9.81 1.01 (0.84–1.21)
FHA (EU/ml) 3.1 2.86 1.08 (0.97–1.21) 2.99 2.97 1.01 (0.90–1.13)
Pertactin (Pm EU/ml) 11.36 10.97 1.04 (0.91–1.17) 10.96 11.36 0.96 (0.84–1.11)
* Bias-corrected accelerated CIs computed by bootstrapping
doi:10.1371/journal.pntd.0005213.t002
Table 3. Subgroup analysis of the effect of randomised maternal treatment on antibody concentrations among infants at one year of age in groups
according to maternal infection status.
Albendazole Praziquantel
Antibody
concentration
Effect of treatment
in women with
hookworm (aGMR,
95% CI)*
Effect of treatment
in women without
hookworm (aGMR,
95% CI)*
P-value for
interaction
Effect of treatment in
women with
schistosomiasis (aGMR,
95% CI)*
Effect of treatment in
women without
schistosomiasis (aGMR,
95% CI)*
P-value for
interaction
HiB (g/ml) 1.03 (0.77–1.38) 1.22 (0.93–1.61) 0.39 0.98 (0.58–1.63) 0.91 (0.73–1.14) 0.80
Diphtheria
(Dtox IU/ml)
0.89 (0.74–1.08) 1.24 (1.04–1.47) 0.01 0.88 (0.66–1.18) 0.94 (0.82–1.08) 0.70
Hepatitis B
(mIU/ml)
0.93 (0.72–1.22) 1.11 (0.88–1.40) 0.33 1.17 (0.76–1.80) 0.79 (0.66–0.95) 0.09
Pertussis toxin
(Ptx EU/ml)
1.10 (0.86–1.42) 1.27 (1.00–1.61) 0.39 1.03 (0.71–1.51) 1.00 (0.82–1.23) 0.89
FHA (EU/ml) 1.17 (0.98–1.41) 1.02 (0.87–1.20) 0.29 1.11 (0.87–1.42) 0.99 (0.86–1.12) 0.44
Pertactin (Pm
EU/ml)
0.99 (0.83–1.18) 1.07 (0.91–1.26) 0.47 1.03 (0.78–1.38) 0.95 (0.83–1.10) 0.58
* Bias-corrected accelerated CIs computed by bootstrapping. All models are adjusted for randomised treatments, maternal age, gravidity, maternal
education, household SES, maternal income, infant sex and previous infant malaria.
doi:10.1371/journal.pntd.0005213.t003
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effects described in each study were necessarily those that occur despite, or in the context of,
these interventions [5].
However, the truth of the matter seems to be that the impact of prenatal parasitic infections
on infant vaccine responses is complex and depends at least on characteristics of both the para-
sitic infection and the vaccine, and on the nature of the desired, protective vaccine response. A
study from Ecuador, in accord with our results, showed no association between maternal geo-
helminths and infant IgG responses to DT, TT, PT, measles, rubella or HiB [16], but several
studies have now indicated a net enhancement of infant vaccine responses following exposure
to certain maternal infections, including Trypanosoma cruzi for BCG, DT, TT and Hep B [17],
maternal intestinal helminth infections and the IgA response to rotavirus and polio (in the
Ecuador study [16]), as well as our result for strongyloidiasis and PT, HiB and Hep B. Mean-
while, Malhotra and colleagues have shown that, for malaria and lymphatic filariasis (and, in
an earlier study, schistosomiasis [18]), the impact of maternal infection on infant vaccine
response depends upon whether or not the infant was sensitised to the parasitic infection in
utero: compared to unexposed infants, malaria sensitised infants showed an increase, and
malaria tolerised infants a decrease, in the response to DT [5]–this may contribute to a neutral
net effect in studies which do not make the same distinction. Like us, Malhotra and colleagues
observed no effect of pre-natal exposure to parasitic infections on infant responses to most of
the EPI vaccines. The principal exception was HiB and, interestingly, although individual
maternal infections were associated with reduced responses, additional infections tended to
reverse this effect. Our findings for HiB followed a similar pattern, although the associations
were not statistically significant.
Our observation of an enhanced response to DT amongst infants of mothers without
hookworm who received albendazole was surprising, and may be a chance finding given that
subgroup analyses were conducted and multiple comparisons were made, with no formal
adjustment in statistical interpretation. However, this result accords with our previous find-
ings of an enhanced IFN-γ response to BCG, an enhanced IL-13 response to TT, and an
enhanced risk of infantile eczema in the same group [7, 19] and suggests a pro-inflammatory
effect of albendazole, in the absence of maternal hookworm, which may be a direct effect of
the drug, or mediated by effects on other co-infections. We think it unlikely that these results
represent an effect of albendazole on light, undetected hookworm infections: as we have pre-
viously reported, a proportion of mothers in the albendazole placebo group had three sam-
ples examined before treatment was given post-delivery, evaluation of which increased the
prevalence of hookworm in this group by only 6% (from 45% to 51%) [19].
A net adverse effect of prenatal exposure to maternal parasitic infections on the induction
of immune responses by vaccines given to the offspring would imply a net adverse effect on
the infant’s ability to respond to pathogens, also. This would be expected to result in increased
neonatal or infant mortality. However, an initial result suggesting that anthelminthic treat-
ment during pregnancy had benefits for infant mortality [20] has not been substantiated in
controlled trials [7, 21]. By contrast, there is considerable evidence that intervention against
malaria during pregnancy has benefits for infant mortality [22]. While this may be mediated
largely by prevention of the major effects of malaria on placental function and fetal growth,
and by effects on infant susceptibility to malaria itself [23, 24], an impact on vaccine responses
and on susceptibility to heterologous infections may contribute. This accords with the rela-
tively prominent suppressive effect of maternal malaria described in Malhotra’s study, with a
reported suppressive effect of prenatal exposure to malaria on the infant response to BCG,
described in The Gambia [25] and with our own previous finding of an association between
maternal malaria and reduced infant antibody response to measles immunisation [26].
Prenatal exposure to parasitic infections and anthelminthic treatment on responses to immunisations
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005213 February 8, 2017 10 / 13
A limitation of our study was that we included just 55% of eligible infants due to incomplete
data. However, the mother-baby pairs that were excluded were similar in known characteris-
tics to those included in the analysis. Further infants were missing from the Hep B analysis. A
limitation of the observational component of our study was the classification of maternal infec-
tion status based on a single blood or stool sample. This would substantially underestimate
and misclassify malaria exposure, which is best assessed by placental histology, and more sensi-
tively assessed by polymerase chain reaction (PCR) assays. The use of a single stool result
would also result in misclassification for hookworm or S. mansoni exposure [27, 28] and hence
may have obscured relevant associations. We have previously reported that in this study the
sensitivity of one stool sample compared with three stool samples was 89% for hookworm
infection and 66% for schistosomiasis [7]. This limitation does not apply to evaluation of Man-
sonella exposure which showed 96% agreement between samples taken in pregnancy and after
delivery in this cohort (2077 of 2162 mothers for whom samples were available at both time
points). Our classification of exposure differed markedly from the classification used by Mal-
hotra and colleagues who included microscopy and PCR on placental and cord blood for
malaria, and assays of circulating antigen and IgG4 for Schistosoma haematobium and Wucher-
eria bancrofti. The use of IgG4 detection as a marker of active infection is of possible concern
as levels may be higher among individuals with a regulatory bias in their immune response
[29]. Contrasting with the time-course described by Malhotra and colleagues, we had data on
vaccine-specific antibody responses only at age one year, but this was a time point at which
many of the effects observed by Malhotra and colleagues were evident, so comparable results
might have been expected. Although other markers or measured timepoints may be more
desirable in terms of assessing true protection against disease (such as neutralisation or func-
tional opsonophagocytic assays [14]), many of these other assays are more prone to inter-
observer error. Our analysis of the unstimulated antibody concentrations maintains consis-
tency between studies and provides observations relating to immunological responses rather
than chances of protection. Furthermore, we had data on a different set of helminth infections
to those used by Malhotra. It could be that particular helminths are more important in deter-
mining vaccine responses of infants, or that there are interaction effects which we have not
explored. This paper contains a large number of estimates, confidence intervals and hypothesis
tests. Due to these multiple comparisons, it is possible that some associations which appear sta-
tistically significant are in fact due to chance alone. These results should therefore not be con-
sidered definitive, but should instead be seen as evidence to be considered alongside other
studies in this field.
From a public health perspective, the additional results that we contribute here accord with
our previous findings [7, 26] and suggest that, whatever its benefits, routine anthelminthic
treatment during pregnancy is not likely to result in improved infant vaccine responses.
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